ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences - February 01, 2023

01 Feb 2023
www.biospace.com
ADCImmunotherapy
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Guggenheim Healthcare Talks 2023 Oncology Conference February 9 at 3:20pm ET SVB Securities Global Biopharma Conference February 15 at 10:00am ET A webcast of each presentation will be accessible through the “Investors and Media” section of the Company’s website, . Following the live webcast, a replay will be available at the same location. ABOUT IMMUNOGEN ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability pro we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™. Learn more about who we are, what we do, and how we do it at . View source version on businesswire.com: Contacts INVESTOR RELATIONS ImmunoGen Anabel Chan 781-895-0600 anabel.chan@immunogen.com MEDIA ImmunoGen Courtney O'Konek 781-895-0600 courtney.okonek@immunogen.com OR FTI Consulting Robert Stanislaro 212-850-5657 robert.stanislaro@fticonsulting.com Source: ImmunoGen, Inc. View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.